systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»10.38109/2075-082X-2025-3-5-18systhiper-852Research ArticleКОНСЕНСУС ЭКСПЕРТОВEXPERT CONSENSUSПрименение бета-адреноблокаторов у пациентов с артериальной гипертониейMedical Society of Hypertension. Use of beta-blockers in patients with hypertensionhttps://orcid.org/0000-0001-5215-4894БлиноваН. В.BlinovaN. V.

Блинова Наталия Владимировна, к.м.н., старший научный сотрудник, отдел гипертонии, Институт клинической кардиологии им. А.Л. Мясникова

ул. Академика Чазова, д. 15а, г. Москва 121552

тел.: 8(495)414-61-86

Nataliya V. Blinova, Cand. of Sci. (Med.), Senior Researcher, Department of Hypertension, A.L. Myasnikov Institute of Clinical Cardiology

St. Academician Chazova, 15 a, Moscow 121552

nat-cardio1@ya.ruhttps://orcid.org/0000-0001-8048-4882АксеноваА. В.AksenovaA. V.

Аксенова Анна Владимировна, к.м.н., старший научный сотрудник, отдел гипертонии, нститут клинической кардиологии им. А.Л. Мясникова

ул. Академика Чазова, д. 15а, г. Москва 121552

Anna V. Aksenova, Cand. of Sci. (Med.), Department of Hypertension, A.L. Myasnikov Institute of Clinical Cardiology

St. Academician Chazova, 15 a, Moscow 121552

aksenovaannav@gmail.comhttps://orcid.org/0000-0002-0758-5609ПодзолковВ. И.PodzolkovV. I.

Подзолков Валерий Иванович, д.м.н., профессор, заведующий кафедрой факультетской терапии № 2, Институт клинической медицины им. Н.В. Склифосовского, директор факультетской терапевтической клиники УКБ №4

ул. Трубецкая, д. 8, стр. 2, г. Москва 119048

Valery I. Podzolkov, Dr. of Sci. (Med.), professor, head of Department of Faculty Therapy No 2, N.V. Sklifosovsky Institute of Clinical Medicine

8/2 Trubetskaya street, Moscow 119048

https://orcid.org/0000-0001-9536-8307ТарзимановаА. И.TarzimanovaA. I.

Тарзиманова Аида Ильгизовна, д.м.н., профессор кафедры факультетской терапии №2, Институт клинической медицины им. Н.В. Склифосовского

ул. Трубецкая, д. 8, стр. 2, г. Москва 119048

Aida I. Tarzimanova, Dr. of Sci. (Med.), Professor, Department of Faculty Therapy No 2, N.V. Sklifosovsky Institute of Clinical Medicine

8/2 Trubetskaya street, Moscow 119048

tarzimanova@mail.ruhttps://orcid.org/0000-0003-1138-3361АмбатьеллоЛ. Г.AmbatielloL. G.

Амбатьелло Лали Гурамовна, к.м.н., старший научный сотрудник, отдел гипертонии, Институт клинической кардиологии им. А.Л. Мясникова

ул. Академика Чазова, д. 15а, г. Москва 121552

тел. +7(495)414-66-02

Lali G. Ambatiello, Cand. Of Sci. (Med.), Senior Researcher, Hypertension Department, A.L. Myasnikov Research Institute of Cardiology

St. Academician Chazova, 15 a, Moscow 121552

lali.ambatiello@mail.ruhttps://orcid.org/0000-0002-9822-4357ЧазоваИ. Е.ChazovaI. E.

Чазова Ирина Евгеньевна, академик РАН, профессор, д.м.н., заместитель генерального директора по научно-экспертной работе, руководитель отдела гипертонии, Институт клинической кардиологии им. А.Л. Мясникова

ул. Академика Чазова, д. 15а, г. Москва 121552

Irina E. Chazova, Academician of RAS, Professor, Dr. of Sci. (Med.), Deputy General Director for Scientific and Expert Work, Head of Hypertension Department, A.L. Myasnikov Research Institute of Cardiology

St. Academician Chazova, 15 a, Moscow 121552

ФГБУ «Национальный медицинский исследовательский центр кардиологии имени академика Е.И. Чазова» Минздрава РоссииРоссияE.I. Chazov National Medical Research Center of CardiologyRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation202529102025223518Copyright © Блинова Н.В., Аксенова А.В., Подзолков В.И., Тарзиманова А.И., Амбатьелло Л.Г., Чазова И.Е., 20252025Блинова Н.В., Аксенова А.В., Подзолков В.И., Тарзиманова А.И., Амбатьелло Л.Г., Чазова И.Е.Blinova N.V., Aksenova A.V., Podzolkov V.I., Tarzimanova A.I., Ambatiello L.G., Chazova I.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/852

В настоящем консенсусе экспертов Российского медицинского общества по артериальной гипертонии представлена роль бета-адреноблокаторов в лечении пациентов с артериальной гипертонией в сочетании как с сердечно-сосудистыми заболеваниями, так и с другой сопутствующей патологией, которая может встречаться у пациентов с АГ чаще, чем у людей с нормальным уровнем артериального давления.

This Russian Medical Society for Arterial Hypertension expert consensus describes the beta-blockers's role in treatment strategy of the arterial hypertension combined with cardiovascular diseases and other comorbidities, which may be more frequent in hypertensive patients than in patients with normal blood pressure level.

антигипертензивные препаратыбета-блокаторыбета-адреноблокаторыартериальное давлениечастота сердечных сокращенийартериальная гипертонияартериальная гипертензиямигреньэректильная дисфункцияхроническая обструктивная болезнь легкихantihypertensive drugsbeta-blockersblood pressureheart ratearterial hypertensionmigraineerectile dysfunctionchronic obstructive pulmonary diseaseReferencesEttehad D., Emdin C.A., Kiran A., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967. https://doi.org/10.1016/S0140-6736(15)01225-8Ettehad D., Emdin C.A., Kiran A., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967. https://doi.org/10.1016/S0140-6736(15)01225-8Чазова И.Е., Чихладзе Н.М., Блинова Н.В., и соавт. Клинические рекомендации Российского медицинского общества по артериальной гипертонии (РМОАГ) и Евразийской Ассоциации Кардиологов (ЕАК) по диагностике и лечению артериальной гипертонии (2024). Системные гипертензии. 25 декабря 2024;21(4):5-109. https://doi.org/10.38109/2075-082X-2024-4-5-109Chazova I.E., Chikhladze N.M., Blinova N.V., et al. Clinical guidelines of the Russian Federationn Medical Society on Arterial Hypertension (RSH) and the Eurasian Association of Cardiologists (EAC) for the diagnosis and treatment of arterial hypertension (2024). Systemic Hypertension. December 25, 2024;21(4):5-109 (in Russ.). https://doi.org/10.38109/2075-082X-2024-4-5-109Wei J., Galaviz K.I., Kowalski A.J., et al. Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications: A Systematic Review and Network Metaanalysis. JAMA. Netw Open 2020;3:e1921618. https://doi.org/10.1001/jamanetworkopen.2019.21618Wei J., Galaviz K.I., Kowalski A.J., et al. Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications: A Systematic Review and Network Metaanalysis. JAMA. Netw Open 2020;3:e1921618. https://doi.org/10.1001/jamanetworkopen.2019.21618Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. J Hypertens. 2015;33:1321-1341. https://doi.org/10.1097/hjh.0000000000000614Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. J Hypertens. 2015;33:1321-1341. https://doi.org/10.1097/hjh.0000000000000614Mancia G., Kreutz R., Brunström M., et al. 2023 ESH Guidelines for the management of arterial hypertension The Task force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal association (ERa). J Hypertens. 2024 Jan 1;42(1):194. https://doi.org/10.1097/HJH.0000000000003621Mancia G., Kreutz R., Brunström M., et al. 2023 ESH Guidelines for the management of arterial hypertension The Task force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal association (ERa). J Hypertens. 2024 Jan 1;42(1):194. https://doi.org/10.1097/HJH.0000000000003621Кобалава Ж.Д., Конради А.О., Недогода С.В., и соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6117. https://doi.org/10.15829/1560-4071-2024-6117Kobalava Zh.D., Konradi A.O., Nedogoda S.V., et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6117do Vale G.T., Ceron C.S., Gonzaga N.A., Simplicio J.A., Padovan J.C. Three generations of b-blockers: history, class differences and clinical applicability. Current hypertension reviews 2019;15:22-31. https://doi.org/10.2174/1573402114666180918102735do Vale G.T., Ceron C.S., Gonzaga N.A., Simplicio J.A., Padovan J.C. Three generations of b-blockers: history, class differences and clinical applicability. Current hypertension reviews 2019;15:22-31. https://doi.org/10.2174/1573402114666180918102735Mancia G., Kjeldsen S.E., Kreutz R., et al. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines. Hypertension. 2022;79(6):1153-1166. https://doi.org/10.1161/HYPERTENSIONaHa.122.19020Mancia G., Kjeldsen S.E., Kreutz R., et al. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines. Hypertension. 2022;79(6):1153-1166. https://doi.org/10.1161/HYPERTENSIONaHa.122.19020Razo C., Welgan C.A., Johnson C.O., et al. Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study. Nat Med. 2022;28(10):2056-2065. https://doi.org/10.1038/s41591-022-01974-1Razo C., Welgan C.A., Johnson C.O., et al. Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study. Nat Med. 2022;28(10):2056-2065. https://doi.org/10.1038/s41591-022-01974-1Lewington S., Clarke R., Qizilbash N., et al. Prospective Studies Collaboration. age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet. 2003 Mar 22;361(9362):1060]. Lancet. 2002;360(9349):1903-1913. https://doi.org/10.1016/s0140-6736(02)11911-8Lewington S., Clarke R., Qizilbash N., et al. Prospective Studies Collaboration. age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet. 2003 Mar 22;361(9362):1060. Lancet. 2002;360(9349):1903-1913. https://doi.org/10.1016/s0140-6736(02)11911-8Vidal-Petiot E., Ford I., Greenlaw N., et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016;388(10056):2142-2152. https://doi.org/10.1016/S0140-6736(16)31326-5Vidal-Petiot E., Ford I., Greenlaw N., et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016;388(10056):2142-2152. https://doi.org/10.1016/S0140-6736(16)31326-5Manolis A.J., Boden W.E., Collins P., et al. State of the art approach to managing angina and ischemia: tailoring treatment to the evidence. Eur J Intern Med. 2021;92:40-47. https://doi.org/10.1016/j.ejim.2021.08.003Manolis A.J., Boden W.E., Collins P., et al. State of the art approach to managing angina and ischemia: tailoring treatment to the evidence. Eur J Intern Med. 2021;92:40-47. https://doi.org/10.1016/j.ejim.2021.08.003Hwang D., Lee J.M., Kim H.K., et al. Prognostic Impact of ?-Blocker Dose after acute Myocardial Infarction. Circ J. 2019;83(2):410-417. https://doi.org/10.1253/circj.CJ-18-0662Hwang D., Lee J.M., Kim H.K., et al. Prognostic Impact of ?-Blocker Dose after acute Myocardial Infarction. Circ J. 2019;83(2):410-417. https://doi.org/10.1253/circj.CJ-18-0662Kolloch R., Legler U.F., Champion a, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008;29(10):1327-1334. https://doi.org/10.1093/eurheartj/ehn123Kolloch R., Legler U.F., Champion a, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008;29(10):1327-1334. https://doi.org/10.1093/eurheartj/ehn123Барбараш О.Л., Карпов Ю.А., Панов А.В., и соавт. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6110. https://doi.org/10.15829/1560-4071-2024-6110Barbarash O.L., Karpov Yu.A., Panov A.V., et al. 2024 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2024;29(9):6110. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6110Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35(11):2150-2160. https://doi.org/10.1097/HJH.0000000000001547Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35(11):2150-2160. https://doi.org/10.1097/HJH.0000000000001547Haider A.W., Larson M.G., franklin S.S., Levy D.; Framingham Heart Study. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the framingham Heart Study. Ann Intern Med. 2003;138(1):10-16. https://doi.org/10.7326/0003-4819-138-1-200301070-00006Haider A.W., Larson M.G., franklin S.S., Levy D.; Framingham Heart Study. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the framingham Heart Study. Ann Intern Med. 2003;138(1):10-16. https://doi.org/10.7326/0003-4819-138-1-200301070-00006McMurray J.J., Packer M., Desai A.S., et al. angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. https://doi.org/10.1056/NEJMoa1409077McMurray J.J., Packer M., Desai A.S., et al. angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. https://doi.org/10.1056/NEJMoa1409077Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JaMa. 1996;275(20):1557-62. PMID: 8622246Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JaMa. 1996;275(20):1557-62. PMID: 8622246Ситникова М.Ю., Лясникова Е.А., Юрченко А.В. и соавт. Результаты Российского госпитального регистра хронической сердечной недостаточности в 3 субъектах Российской Федерации. Кардиология 2015;10:5-13. https://doi.org/10.18565/cardio.2015.10.5-13Sitnikova MYS, Lyasnikova EaL, et al. Results of Russian Hospital Chronic Heart failure Registry in Three Subjects of Russian federation. Kardiologiia 2015;10:5-13. (In Russ.) https://doi.org/10.18565/cardio.2015.10.5-13Терещенко С.Н., Жиров И.В., Ускач Т.М., и соавт. Клинические рекомендации Евразийской Ассоциации Кардиологов (ЕАК)/ Национального общества по изучению сердечной недостаточности и заболеваний миокарда (НОИСН) по диагностике и лечению хронической сердечной недостаточности (2024). Евразийский кардиологический журнал. Май 2024;(2):6-76. https://doi.org/10.38109/2225-1685-2024-2-6-76Tereshchenko S.N., Zhirov I.V., Uskach T.M., et al. Eurasian Association of Cardiology (EAC)/ National Society of Heart Failure And Myocardial Disease (NSHFMD) guidelines for the diagnosis and treatment of chronic heart failure (2024). Eurasian heart journal. 2024;(2):6-76. (In Russ.) https://doi.org/10.38109/2225-1685-2024-2-6-76Gattis W.A., O’Connor C.M., Leimberger J.D., et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol 2003;91:169-74. https://doi.org/10.1016/S0002-9149(02)03104-1Gattis W.A., O’Connor C.M., Leimberger J.D., et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol 2003;91:169-74. https://doi.org/10.1016/S0002-9149(02)03104-1Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001;357:1385-90. https://doi.org/10.1016/S0140-6736(00)04560-8Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001;357:1385-90. https://doi.org/10.1016/S0140-6736(00)04560-8Cleland J.G.F., Bunting K.V., Flather M.D., et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26-35. https://doi.org/10.1093/eurheartj/ehx564Cleland J.G.F., Bunting K.V., Flather M.D., et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26-35. https://doi.org/10.1093/eurheartj/ehx564Чазова И.Е., Голицын С.П., Жернакова Ю.В. и др. Ведение пациентов с артериальной гипертонией и фибрилляцией предсердий. Системные гипертензии. 2021;18(3):105-128. https://doi.org/10.26442/2075082X.2021.3.201077Chazova I.E., Golitsyn S.P., Zhernakova J.V., Zheleznova E.A., et al. Management of patients with arterial hypertension and atrial fibrillation. Systemic Hypertension. 2021;18(3):105-128. (In Russ.) https://doi.org/10.26442/2075082X.2021.3.201077Попов С.В., Давтян К.В., Шубик Ю.В. и др. Наджелудочковые тахикардии. Клинические рекомендации 2025. Российский кардиологический журнал. 2025; 30(7):6448. EDN: ZLGSCN https://doi.org/10.15829/1560-4071-2025-6448Popov S.V., Davtyan K.V., Shubik Yu.V., et al. 2025 Clinical practice guidelines for Supraventricular tachycardias. Russian Journal of Cardiology. 2025;30(7):6448. (In Russ.) EDN: ZLGSCN https://doi.org/10.15829/1560-4071-2025-6448Van Gelder I.C., Rienstra M., Bunting K.V. et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for CardioThoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. https://doi.org/10.1093/eurheartj/ehae176Van Gelder I.C., Rienstra M., Bunting K.V. et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for CardioThoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. https://doi.org/10.1093/eurheartj/ehae176Grandi E., Ripplinger C.M. Antiarrhythmic mechanisms of beta blocker therapy. Pharmacol Res. 2019 Aug;146:104274. Epub 2019 May 14. PMID: 31100336; PMCID: PMC6679787. https://doi.org/10.1016/j.phrs.2019.104274Grandi E., Ripplinger C.M. Antiarrhythmic mechanisms of beta blocker therapy. Pharmacol Res. 2019 Aug;146:104274. Epub 2019 May 14. PMID: 31100336; PMCID: PMC6679787. https://doi.org/10.1016/j.phrs.2019.104274Olshansky B., Rosenfeld L.E., Warner A.L. et al. AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004 Apr 7;43(7):1201-8. PMID: 15063430. https://doi.org/10.1016/j.jacc.2003.11.032Olshansky B., Rosenfeld L.E., Warner A.L. et al. AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004 Apr 7;43(7):1201-8. PMID: 15063430. https://doi.org/10.1016/j.jacc.2003.11.032Piccini, J. P., Hranitzky, P. M., Kilaru, R. et al. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan in Acute myocardial iNfarcTion trial [VALIANT] Registry). Am. J. Cardiol. 2008: 102, 1427-1432. https://doi.org/10.1016/j.amjcard.2008.07.033Piccini, J. P., Hranitzky, P. M., Kilaru, R. et al. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan in Acute myocardial iNfarcTion trial [VALIANT Registry). Am. J. Cardiol. 2008: 102, 1427-1432. https://doi.org/10.1016/j.amjcard.2008.07.033Zeitler E.P., Al-Khatib S.M., Friedman D.J., et al. Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT II. J Cardiovasc Electrophysiol. 2017 Nov;28(11):1345-1351. Epub 2017 Aug 23. PMID: 28744959; PMCID: PMC5693305. https://doi.org/10.1111/jce.13307Zeitler E.P., Al-Khatib S.M., Friedman D.J., et al. Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT II. J Cardiovasc Electrophysiol. 2017 Nov;28(11):1345-1351. Epub 2017 Aug 23. PMID: 28744959; PMCID: PMC5693305. https://doi.org/10.1111/jce.13307Wołowiec Ł., Grześk G., Osiak J. et al. Beta-blockers in cardiac arrhythmias-Clinical pharmacologist's point of view. Front Pharmacol. 2023 Jan 9;13:1043714. PMID: 36699057; PMCID: PMC9868422. https://doi.org/10.3389/fphar.2022.1043714Wołowiec Ł., Grześk G., Osiak J. et al. Beta-blockers in cardiac arrhythmias-Clinical pharmacologist's point of view. Front Pharmacol. 2023 Jan 9;13:1043714. PMID: 36699057; PMCID: PMC9868422. https://doi.org/10.3389/fphar.2022.1043714Muresan L., Cismaru G., Muresan C. et al. Beta-blockers for the treatment of arrhythmias: Bisoprolol – a systematic review. Ann Pharm Fr. 2022 Sep;80(5):617-634. Epub 2022 Jan 31. PMID: 35093388. https://doi.org/10.1016/j.pharma.2022.01.007Muresan L., Cismaru G., Muresan C. et al. Beta-blockers for the treatment of arrhythmias: Bisoprolol – a systematic review. Ann Pharm Fr. 2022 Sep;80(5):617-634. Epub 2022 Jan 31. PMID: 35093388. https://doi.org/10.1016/j.pharma.2022.01.007Olshansky B., Sullivan R.M. Inappropriate sinus tachycardia. Europace. 2019 Feb 1;21(2):194-207. PMID: 29931244. https://doi.org/10.1093/europace/euy128Olshansky B., Sullivan R.M. Inappropriate sinus tachycardia. Europace. 2019 Feb 1;21(2):194-207. PMID: 29931244. https://doi.org/10.1093/europace/euy128Brugada J., Katritsis D.G., Arbelo E., et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655-720. https://doi.org/10.1093/eurheartj/ehz467Brugada J., Katritsis D.G., Arbelo E., et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655-720. https://doi.org/10.1093/eurheartj/ehz467Rehnqvist N. Clinical experience with intravenous metoprolol in supraventricular tachyarrhythmias. A multicentre study. Ann Clin Res. 1981;13 Suppl 30:68-72. PMID: 7027895Rehnqvist N. Clinical experience with intravenous metoprolol in supraventricular tachyarrhythmias. A multicentre study. Ann Clin Res. 1981;13 Suppl 30:68-72. PMID: 7027895Arsura E., Lefkin A.S., Scher D.L., et al. A randomized, double-blind, placebo-controlled study of verapamil and metoprolol in treatment of multifocal atrial tachycardia. Am J Med. 1988 Oct;85(4):519-24. https://doi.org/10.1016/s0002-9343(88)80088-3. Erratum in: Am J Med 1989 Jan;86(1):142. PMID: 3052051. https://doi.org/10.1016/s0002-9343(88)80088-3Arsura E., Lefkin A.S., Scher D.L., et al. A randomized, double-blind, placebo-controlled study of verapamil and metoprolol in treatment of multifocal atrial tachycardia. Am J Med. 1988 Oct;85(4):519-24. https://doi.org/10.1016/s0002-9343(88)80088-3. Erratum in: Am J Med 1989 Jan;86(1):142. PMID: 3052051. https://doi.org/10.1016/s0002-9343(88)80088-3Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet. 1999;354(9192):1751-6. https://doi.org/10.1016/S0140-6736(99)10327-1Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet. 1999;354(9192):1751-6. https://doi.org/10.1016/S0140-6736(99)10327-1Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353(9153):611-6. https://doi.org/10.1016/S0140-6736(98)05012-0Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353(9153):611-6. https://doi.org/10.1016/S0140-6736(98)05012-0Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. https://doi.org/10.1016/S0140-6736(02)08089-3Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. https://doi.org/10.1016/S0140-6736(02)08089-3Тарзиманова А.И., Исаева А.Ю. Новые возможности антиаритмической терапии фибрилляции предсердий. Терапевтический архив. 2024;96(2):181-185. https://doi.org/10.26442/00403660.2024.02.202585Tarzimanova A.I., Isaeva A.I. New possibilities of antiarrhythmic therapy of atrial fibrillation: A review. Terapevticheskii arkhiv 2024;96(2):181-185. https://doi.org/10.26442/00403660.2024.02.202585Mulder B.A., Van Veldhuisen D.J., Crijns H.J. et al. RACE II Investigators. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm. 2014 Sep;11(9):1543-50. Epub 2014 Jun 9. PMID: 24924587. https://doi.org/10.1016/j.hrthm.2014.06.007Mulder B.A., Van Veldhuisen D.J., Crijns H.J. et al. RACE II Investigators. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm. 2014 Sep;11(9):1543-50. Epub 2014 Jun 9. PMID: 24924587. https://doi.org/10.1016/j.hrthm.2014.06.007Kotecha D., Bunting K.V., Gill S.K. et al. Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on PatientReported Quality of Life: The RATE-AF Randomized Clinical Trial. JAMA. 2020 Dec 22;324(24):2497-2508. PMID: 33351042; PMCID: PMC7756234. https://doi.org/10.1001/jama.2020.23138Kotecha D., Bunting K.V., Gill S.K. et al. Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on PatientReported Quality of Life: The RATE-AF Randomized Clinical Trial. JAMA. 2020 Dec 22;324(24):2497-2508. PMID: 33351042; PMCID: PMC7756234. https://doi.org/10.1001/jama.2020.23138Karwath A., Bunting K.V., Gill S.K. et al. Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis. Lancet. 2021 Oct 16;398(10309):1427-1435. Epub 2021 Aug 30. PMID: 34474011; PMCID: PMC8542730. https://doi.org/10.1016/S0140-6736(21)01638-XKarwath A., Bunting K.V., Gill S.K. et al. Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis. Lancet. 2021 Oct 16;398(10309):1427-1435. Epub 2021 Aug 30. PMID: 34474011; PMCID: PMC8542730. https://doi.org/10.1016/S0140-6736(21)01638-XCrystal E., Garfinkle M.S., Connolly S.S., et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003611. https://doi.org/10.1002/14651858.cd003611.pub2Crystal E., Garfinkle M.S., Connolly S.S., et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003611. https://doi.org/10.1002/14651858.cd003611.pub2Zeppenfeld K., Tfelt-Hansen J., de Riva M. et al. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126. PMID: 36017572. https://doi.org/10.1093/eurheartj/ehac262Zeppenfeld K., Tfelt-Hansen J., de Riva M. et al. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126. PMID: 36017572. https://doi.org/10.1093/eurheartj/ehac262Schupp T., Behnes M., Weiß C. et al. Beta-Blockers and ACE Inhibitors Are Associated with Improved Survival Secondary to Ventricular Tachyarrhythmia. Cardiovasc Drugs Ther. 2018 Aug;32(4):353-363. PMID: 30074111. https://doi.org/10.1007/s10557-018-6812-zSchupp T., Behnes M., Weiß C. et al. Beta-Blockers and ACE Inhibitors Are Associated with Improved Survival Secondary to Ventricular Tachyarrhythmia. Cardiovasc Drugs Ther. 2018 Aug;32(4):353-363. PMID: 30074111. https://doi.org/10.1007/s10557-018-6812-zЖернакова Ю.В., Азимова М.О., Железнова Е.А., и др. Оценка распространенности поражения органов-мишеней на различных этапах кардиометаболического континуума. По данным исследования ЭССЕ РФ. Системные гипертензии. 2022;19(3):31-39. https://doi.org/10.38109/2075-082X-2022-3-31-39Zhernakova Yu.V., azimova M.O., Zheleznova E.А., et al. assessment of the prevalence of target organ damage at various stages of the cardiometabolic continuum. according to the ESSE Rf study. Systemic Hypertension. 2022;19(3):31-39. (In Russ.) https://doi.org/10.38109/2075-082X-2022-3-31-39Жернакова Ю.В., Чазова И.Е., Ощепкова Е.В. и др. Распространенность сахарного диабета в популя ции больных артериальной гипертонией. По данным исследования ЭССЕ-РФ. Системные гипертензии. 2018;15(1):56-62. https://doi.org/10.26442/2075-082X_15.1.56-62Zhernakova Yu.V., Chazova I.E., Oshchepkova E.V., et al. The prevalence of diabetes mellitus in population of hypertensive patients according to ESSE Rf study results. Systemic Hypertension. 2018;15(1):56-62. (In Russ.) https://doi.org/10.26442/2075-082X_15.1.56-62Chen S., Tian P., Estau D., Li Z. Effects of β-blockers on all-cause mortality in patients with diabetes and coronary heart disease: A systematic review and meta-analysis. Front Cell Dev Biol. 2023;11:1076107. Published 2023 Jan 27. https://doi.org/10.3389/fcell.2023.1076107Chen S., Tian P., Estau D., Li Z. Effects of β-blockers on all-cause mortality in patients with diabetes and coronary heart disease: A systematic review and meta-analysis. Front Cell Dev Biol. 2023;11:1076107. Published 2023 Jan 27. https://doi.org/10.3389/fcell.2023.1076107Hirst J.A., Farmer A.J., Feakins B.G., Aronson J.K., Stevens R. Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus – a systematic review and metaanalysis. Br J Clin Pharmacol. 2015;79(5):733-743. https://doi.org/10.1111/bcp.12543Hirst J.A., Farmer A.J., Feakins B.G., Aronson J.K., Stevens R. Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus – a systematic review and metaanalysis. Br J Clin Pharmacol. 2015;79(5):733-743. https://doi.org/10.1111/bcp.12543Cosentino F., Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. https://doi.org/10.1093/eurheartj/ehz486Cosentino F., Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. https://doi.org/10.1093/eurheartj/ehz486Чазова И.Е., Шестакова М.В., Жернакова Ю.В., и соавт. Евразийские рекомендации по профилактике и лечению сердечно-сосудистых заболеваний у больных с диабетом и предиабетом (2021). Евразийский Кардиологический Журнал. 2021;(2):6-61. https://doi.org/10.38109/2225-1685-2021-2-6-61Chazova I.E., Shestakova M.V., Zhernakova Yu.V., et al. Eurasian association of cardiology (eac) guidelines for the prevention and treatment of cardiovascular diseases in patients with diabetes and prediabetes (2021). Eurasian heart journal. 2021;(2):6-61. (In Russ.) https://doi.org/10.38109/2225-1685-2021-2-6-61Carella A.M., Antonucci G., Conte M., et al. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Curr. Diabetes Rev. 2010; 6 (4): 215-221. https://doi.org/10.2174/157339910791658844Carella A.M., Antonucci G., Conte M., et al. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Curr. Diabetes Rev. 2010; 6 (4): 215-221. https://doi.org/10.2174/157339910791658844Bakris G.L., Fonseca V., Katholi R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227-2236. https://doi.org/10.1001/jama.292.18.2227Bakris G.L., Fonseca V., Katholi R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227-2236. https://doi.org/10.1001/jama.292.18.2227Schmidt A.C., Graf C., Brixius K., Scholze J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig. 2007;27(12):841-849. https://doi.org/10.2165/00044011-200727120-00006Schmidt A.C., Graf C., Brixius K., Scholze J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig. 2007;27(12):841-849. https://doi.org/10.2165/00044011-200727120-00006Чазова И.Е., Невзорова В.А., Амбатьелло Л.Г. и др. Клинические рекомендации по диагностике и лечению пациентов с артериальной гипертонией и хронической обструктивной болезнью легких. Системные гипертензии. 2020;17(3):7-34 https://doi.org/10.26442/2075082X.2020.3.200294Chazova I.E., Nevzorova V.A., Ambatiello L.G., et al. Clinical practice guidelines on the diagnosis and treatment of patients with arterial hypertension and chronic obstructive pulmonary disease. Systemic Hypertension. 2020;17(3):7-34. (In Russ.) https://doi.org/10.26442/2075082X.2020.3.200294Климова АА, Амбатьелло ЛГ, Смолякова ЕВ и др. Частота выявления сочетанной бронхообструктивной патологии у пациентов с артериальной гипертонией, поступающих в специализированный кардиологический стационар. Системные гипертензии. 2023;20(1):35-43 https://doi.org/10.38109/2075-082X-2023-1-35-43Klimova A.A., Ambatello L.G., Smolyakova E.V., et al. The frequency of detection of comorbid bronchoobstructive pathology in patients with arterial hypertension admitted to a specialized cardiological hospital. Systemic Hypertension. 2023;20(1):35-43. (In Russ.) https://doi.org/10.38109/2075-082X-2023-1-35-43Dhungel S., Paudel B., Shah S. Study of prevalence of hypertension in Chronic Obstructive Pulmonary Disease patients admitted at Nepal Medical College and Teaching Hospital. Nepal Medical College Journal. 2005;7(2):90‑92. PMID: 16519071Dhungel S., Paudel B., Shah S. Study of prevalence of hypertension in Chronic Obstructive Pulmonary Disease patients admitted at Nepal Medical College and Teaching Hospital. Nepal Medical College Journal. 2005;7(2):90‑92. PMID: 16519071McGavin C.R., Williams I.P. The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction. Br J Dis Chest 1978;72(4):327-32. PMID: 365214McGavin C.R., Williams I.P. The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction. Br J Dis Chest 1978;72(4):327-32. PMID: 365214Brooks Т.W., Creekmore F.M., Young D.C. at al. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy. 2007;27(5):684-90. https://doi.org/10.1592/phco.27.5.684Brooks Т.W., Creekmore F.M., Young D.C. at al. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy. 2007;27(5):684-90. https://doi.org/10.1592/phco.27.5.684Salpeter S., Ormiston T., Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;2005(4):CD003566. Published 2005 Oct 19. https://doi.org/10.1002/14651858.CD003566.pub2Salpeter S., Ormiston T., Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;2005(4):CD003566. Published 2005 Oct 19. https://doi.org/10.1002/14651858.CD003566.pub2Ni Y., Shi G., Wan H. Use of Cardioselective b-Blockers in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Placebo-controlled, Blinded Trials. J Int Med Res 2012;40(6):2051-65. https://doi.org/10.1177/030006051204000602Ni Y., Shi G., Wan H. Use of Cardioselective b-Blockers in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Placebo-controlled, Blinded Trials. J Int Med Res 2012;40(6):2051-65. https://doi.org/10.1177/030006051204000602Leitao Filho FS, Choi L, Sin DD. Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly. Curr Opin Pulm Med. 2021 Mar 1;27(2):125-131. https://doi.org/10.1097/MCP.0000000000000748Leitao Filho FS, Choi L, Sin DD. Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly. Curr Opin Pulm Med. 2021 Mar 1;27(2):125-131. https://doi.org/10.1097/MCP.0000000000000748Lin R., Peng H., Nguyen L.P., et al. Changes in beta 2-adrenoreceptor and other signaling proteins produced by chronic administration of “beta blockers” in a murine asthma model. Pulm Pharmacol Ther 2008;21:115-24. https://doi.org/10.1016/j.pupt.2007.06.003Lin R., Peng H., Nguyen L.P., et al. Changes in beta 2-adrenoreceptor and other signaling proteins produced by chronic administration of “beta blockers” in a murine asthma model. Pulm Pharmacol Ther 2008;21:115-24. https://doi.org/10.1016/j.pupt.2007.06.003Short P.M., Lipworth S.I., Elder D.H., Schembri S., Lipworth B.J. Effect of b-blockers in treatment of chronic obstructive pulmonary disease: a retro spective cohort study. BMJ 2011;342:d2549. https://doi.org/10.1136/bmj.d2549Short P.M., Lipworth S.I., Elder D.H., Schembri S., Lipworth B.J. Effect of b-blockers in treatment of chronic obstructive pulmonary disease: a retro spective cohort study. BMJ 2011;342:d2549. https://doi.org/10.1136/bmj.d2549Dal Negro R. Pulmonary effects of nebivolol. Ther Adv Cardiovasc Dis. 2009;3(4):329-334. https://doi.org/10.1177/1753944709339968Dal Negro R. Pulmonary effects of nebivolol. Ther Adv Cardiovasc Dis. 2009;3(4):329-334. https://doi.org/10.1177/1753944709339968Stefan M.S., Rothberg M.B., Priya A., Pekow P.S., Au D.H., Lindenauer P.K. Association between b-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012;67:977-84. https://doi.org/10.1136/thoraxjnl-2012-201945Stefan M.S., Rothberg M.B., Priya A., Pekow P.S., Au D.H., Lindenauer P.K. Association between b-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012;67:977-84. https://doi.org/10.1136/thoraxjnl-2012-201945Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300. https://doi.org/10.1016/j.amjmed.2008.09.038Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300. https://doi.org/10.1016/j.amjmed.2008.09.038Lammers J.W., Folgering H.T., van Herwaarden C.L. Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. J Cardiovasc Pharmacol 1986:8 Suppl 11:S69-73. https://doi.org/10.1097/00005344-198511001-00012Lammers J.W., Folgering H.T., van Herwaarden C.L. Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. J Cardiovasc Pharmacol 1986:8 Suppl 11:S69-73. https://doi.org/10.1097/00005344-198511001-00012Lawrence D.S., Sahay J.N., Chatterjee S.S., Cruickshank J.M. Asthma and beta-blockers. Eur J Clin Pharmacol 1982;22(6):501-9. https://doi.org/10.1007/BF00609622Lawrence D.S., Sahay J.N., Chatterjee S.S., Cruickshank J.M. Asthma and beta-blockers. Eur J Clin Pharmacol 1982;22(6):501-9. https://doi.org/10.1007/BF00609622Huang K., Tseng P., Wu Y. at al. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials. Sci Rep. 2021 Jan 11;11(1):452. https://doi.org/10.1038/s41598-020-79837-3Huang K., Tseng P., Wu Y. at al. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials. Sci Rep. 2021 Jan 11;11(1):452. https://doi.org/10.1038/s41598-020-79837-3Marko M., Pawliczak R. An updated insight into the effect of β-adrenergic receptor antagonists (β-blockers) on respiratory function in asthma patients: a systematic review and meta-analysis. Front Physiol. 2025 Jul 25;16:1582740. https://doi.org/10.3389/fphys.2025.1582740Marko M., Pawliczak R. An updated insight into the effect of β-adrenergic receptor antagonists (β-blockers) on respiratory function in asthma patients: a systematic review and meta-analysis. Front Physiol. 2025 Jul 25;16:1582740. https://doi.org/10.3389/fphys.2025.1582740Itoga N.K., Tawfik D.S., Lee C.K., Maruyama S., Leeper N.J., Chang T.I. Association of Blood Pressure Measurements With Peripheral Artery Disease Events. Circulation. 2018;138(17):1805-1814. https://doi.org/10.1161/CIRCULATIONAHA.118.033348Itoga N.K., Tawfik D.S., Lee C.K., Maruyama S., Leeper N.J., Chang T.I. Association of Blood Pressure Measurements With Peripheral Artery Disease Events. Circulation. 2018;138(17):1805-1814. https://doi.org/10.1161/CIRCULATIONAHA.118.033348Thomas Manapurathe D., Krishna S.M., Dewdney B., Moxon J.V., Biros E., Golledge J. Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: A meta-analysis of randomised controlled trials. PLoS One. 2017;12(6):e0178713. Published 2017 Jun 2. https://doi.org/10.1371/journal.pone.0178713Thomas Manapurathe D., Krishna S.M., Dewdney B., Moxon J.V., Biros E., Golledge J. Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: A meta-analysis of randomised controlled trials. PLoS One. 2017;12(6):e0178713. Published 2017 Jun 2. https://doi.org/10.1371/journal.pone.0178713Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013;2013(9):CD005508. Published 2013 Sep 11. https://doi.org/10.1002/14651858.CD005508.pub3Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013;2013(9):CD005508. Published 2013 Sep 11. https://doi.org/10.1002/14651858.CD005508.pub3Paravastu S.C., Mendonca D.A., da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38(1):66-70. https://doi.org/10.1016/j.ejvs.2009.02.019Paravastu S.C., Mendonca D.A., da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38(1):66-70. https://doi.org/10.1016/j.ejvs.2009.02.019Espinola-Klein C., Weisser G., Jagodzinski A., et al. β-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011;58(2):148-154. https://doi.org/10.1161/HYPERTENSIONAHA.110.169169Espinola-Klein C., Weisser G., Jagodzinski A., et al. β-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011;58(2):148-154. https://doi.org/10.1161/HYPERTENSIONAHA.110.169169Rabkin R., Stables D.P., Levin N.W., Suzman M.M. The prophylactic value of propranolol in angina pectoris. Am J Cardiol. 1966;18(3):370-383. https://doi.org/10.1016/0002-9149(66)90056-7Rabkin R., Stables D.P., Levin N.W., Suzman M.M. The prophylactic value of propranolol in angina pectoris. Am J Cardiol. 1966;18(3):370-383. https://doi.org/10.1016/0002-9149(66)90056-7Rubio-Beltrán E., Schoon R.M., van den Berg J., et al. Trigeminovascular effects of propranolol in men and women, role for sex steroids. Ann Clin Transl Neurol. 2022;9(9):1405-1416. https://doi.org/10.1002/acn3.51640Rubio-Beltrán E., Schoon R.M., van den Berg J., et al. Trigeminovascular effects of propranolol in men and women, role for sex steroids. Ann Clin Transl Neurol. 2022;9(9):1405-1416. https://doi.org/10.1002/acn3.51640Shields K.G., Goadsby P.J. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain. 2005;128(Pt 1):86-97. https://doi.org/10.1093/brain/awh298Shields K.G., Goadsby P.J. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain. 2005;128(Pt 1):86-97. https://doi.org/10.1093/brain/awh298Ayata C., Jin H., Kudo C., Dalkara T., Moskowitz M.A. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59(4):652-661. https://doi.org/10.1002/ana.20778Ayata C., Jin H., Kudo C., Dalkara T., Moskowitz M.A. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59(4):652-661. https://doi.org/10.1002/ana.20778Jackson JL, Kuriyama A, Kuwatsuka Y, et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One. 2019;14(3):e0212785. Published 2019 Mar 20. https://doi.org/10.1371/journal.pone.0212785Jackson JL, Kuriyama A, Kuwatsuka Y, et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One. 2019;14(3):e0212785. Published 2019 Mar 20. https://doi.org/10.1371/journal.pone.0212785Fumagalli C., Maurizi N., Marchionni N., Fornasari D. β-blockers: Their new life from hypertension to cancer and migraine. Pharmacol Res. 2020;151:104587. https://doi.org/10.1016/j.phrs.2019.104587Fumagalli C., Maurizi N., Marchionni N., Fornasari D. β-blockers: Their new life from hypertension to cancer and migraine. Pharmacol Res. 2020;151:104587. https://doi.org/10.1016/j.phrs.2019.104587Adham N., Ellerbrock B., Hartig P., Weinshank R.L., Branchek T. Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system. Mol Pharmacol. 1993;43(3):427-433. PMID: 8095694.Adham N., Ellerbrock B., Hartig P., Weinshank R.L., Branchek T. Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system. Mol Pharmacol. 1993;43(3):427-433. PMID: 8095694.Versijpt J., Deligianni C., Hussain M., et al. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention – part 4: propranolol. J Headache Pain. 2024;25(1):119. Published 2024 Jul 24. https://doi.org/10.1186/s10194-024-01826-yVersijpt J., Deligianni C., Hussain M., et al. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention – part 4: propranolol. J Headache Pain. 2024;25(1):119. Published 2024 Jul 24. https://doi.org/10.1186/s10194-024-01826-yКлинические рекомендации Минздрава России. Мигрень, 2024 г. https://cr.minzdrav.gov.ru/preview-cr/295_4Clinical guidelines of the Russian Ministry of Health. Migraine, 2024. (In Russ.) https://cr.minzdrav.gov.ru/preview-cr/295_4Landgren A.J., Dehlin M., Jacobsson L., Bergsten U., Klingberg E. Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden. RMD Open. 2021;7(2):e001568. https://doi.org/10.1136/rmdopen-2021-001568Landgren A.J., Dehlin M., Jacobsson L., Bergsten U., Klingberg E. Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden. RMD Open. 2021;7(2):e001568. https://doi.org/10.1136/rmdopen-2021-001568Mehta N.N., Yu Y., Pinnelas R., et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775.e1-775.e7756. https://doi.org/10.1016/j.amjmed.2011.03.028Mehta N.N., Yu Y., Pinnelas R., et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775.e1-775.e7756. https://doi.org/10.1016/j.amjmed.2011.03.028Hu X., Li J., Fu M., Zhao X., Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. Published 2021 Nov 26. https://doi.org/10.1038/s41392-021-00791-1Hu X., Li J., Fu M., Zhao X., Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. Published 2021 Nov 26. https://doi.org/10.1038/s41392-021-00791-1Song G., Kim J.Y., Yoon H.Y., Yee J., Gwak H.S. A systematic review and meta-analysis of angiotensinconverting enzyme inhibitor use and psoriasis incidence. Sci Rep. 2021;11(1):10037. Published 2021 May 11. https://doi.org/10.1038/s41598-021-89490-zSong G., Kim J.Y., Yoon H.Y., Yee J., Gwak H.S. A systematic review and meta-analysis of angiotensinconverting enzyme inhibitor use and psoriasis incidence. Sci Rep. 2021;11(1):10037. Published 2021 May 11. https://doi.org/10.1038/s41598-021-89490-zGaneva M., Tsokeva Z., Gancheva T., Hristakieva E., Tsoneva V., Manolova I. Serum concentrations of 25-OH vitamin D and the pro-inflammatory interleukins IL-17, IL-23, and IL-18 in patients with plaque psoriasis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024;168(2):124-131. https://doi.org/10.5507/bp.2023.043Ganeva M., Tsokeva Z., Gancheva T., Hristakieva E., Tsoneva V., Manolova I. Serum concentrations of 25-OH vitamin D and the pro-inflammatory interleukins IL-17, IL-23, and IL-18 in patients with plaque psoriasis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024;168(2):124-131. https://doi.org/10.5507/bp.2023.043Azzouz B., De Guizelin A., Lambert A., Fresse A., Morel A., Trenque T. Psoriasis risk after beta-blocker exposure: Description of a pharmacovigilance signal. Br J Clin Pharmacol. 2022;88(8):3813-3818. https://doi.org/10.1111/bcp.15330Azzouz B., De Guizelin A., Lambert A., Fresse A., Morel A., Trenque T. Psoriasis risk after beta-blocker exposure: Description of a pharmacovigilance signal. Br J Clin Pharmacol. 2022;88(8):3813-3818. https://doi.org/10.1111/bcp.15330Dodulík J., Dodulíková L., Plášek J., Ramík Z., Vrtal J., Václavík J. Pharmacotherapy of arterial hypertension in patients with psoriasis. J Hypertens. 2025;43(4):568-576. https://doi.org/10.1097/HJH.0000000000003982Dodulík J., Dodulíková L., Plášek J., Ramík Z., Vrtal J., Václavík J. Pharmacotherapy of arterial hypertension in patients with psoriasis. J Hypertens. 2025;43(4):568-576. https://doi.org/10.1097/HJH.0000000000003982NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270(1):83-90. PMID: 8510302.NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270(1):83-90. PMID: 8510302.Korneyev I.A., Alexeeva T.A., Al-Shukri S.H., et al. Prevalence and risk factors for erectile dysfunction and lower urinary tract symptoms in Russian Federation men: analysis from a national population-based multicenter study. Int J Impot Res. 2016;28(2):74-79. https://doi.org/10.1038/ijir.2016.8Korneyev I.A., Alexeeva T.A., Al-Shukri S.H., et al. Prevalence and risk factors for erectile dysfunction and lower urinary tract symptoms in Russian Federation men: analysis from a national population-based multicenter study. Int J Impot Res. 2016;28(2):74-79. https://doi.org/10.1038/ijir.2016.8Doumas M., Douma S. Sexual dysfunction in essential hypertension: myth or reality? J Clin Hypertens (Greenwich). 2006;8(4):269-274. https://doi.org/10.1111/j.1524-6175.2006.04708.xDoumas M., Douma S. Sexual dysfunction in essential hypertension: myth or reality? J Clin Hypertens (Greenwich). 2006;8(4):269-274. https://doi.org/10.1111/j.1524-6175.2006.04708.xDoumas M., Tsiodras S., Tsakiris A., et al. Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens. 2006;24(12):2387-2392. https://doi.org/10.1097/01.hjh.0000251898.40002.5bDoumas M., Tsiodras S., Tsakiris A., et al. Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens. 2006;24(12):2387-2392. https://doi.org/10.1097/01.hjh.0000251898.40002.5bКлинические рекомендации «Эректильная дисфункция», 2025. Одобрено МЗ РФ, Российское общество урологов.Clinical guidelines "Erectile dysfunction", 2025. Approved by the Russian Ministry of Health, Russian Society of Urologists. (In Russ.)Farmakis I.T., Pyrgidis N., Doundoulakis I., Mykoniatis I., Akrivos E., Giannakoulas G. Effects of Major Antihypertensive Drug Classes on Erectile Function: a Network Meta-analysis. Cardiovasc Drugs Ther. 2022;36(5):903-914. https://doi.org/10.1007/s10557-021-07197-9Farmakis I.T., Pyrgidis N., Doundoulakis I., Mykoniatis I., Akrivos E., Giannakoulas G. Effects of Major Antihypertensive Drug Classes on Erectile Function: a Network Meta-analysis. Cardiovasc Drugs Ther. 2022;36(5):903-914. https://doi.org/10.1007/s10557-021-07197-9Silvestri A., Galetta P., Cerquetani E., et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24(21):1928-1932. https://doi.org/10.1016/j.ehj.2003.08.016Silvestri A., Galetta P., Cerquetani E., et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24(21):1928-1932. https://doi.org/10.1016/j.ehj.2003.08.016Nehra A., Jackson G., Miner M., et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766-778. https://doi.org/10.1016/j.mayocp.2012.06.015Nehra A., Jackson G., Miner M., et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766-778. https://doi.org/10.1016/j.mayocp.2012.06.015Viigimaa M., Vlachopoulos C., Doumas M., et al. Update of the position paper on arterial hypertension and erectile dysfunction. J Hypertens. 2020;38(7):1220-1234. https://doi.org/10.1097/HJH.0000000000002382Viigimaa M., Vlachopoulos C., Doumas M., et al. Update of the position paper on arterial hypertension and erectile dysfunction. J Hypertens. 2020;38(7):1220-1234. https://doi.org/10.1097/HJH.0000000000002382Fogari R., Preti P., Zoppi A., et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens. 2004;17(1):77-81. https://doi.org/10.1016/j.amjhyper.2003.08.016Fogari R., Preti P., Zoppi A., et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens. 2004;17(1):77-81. https://doi.org/10.1016/j.amjhyper.2003.08.016Doumas M., Douma S. The effect of antihypertensive drugs on erectile function: a proposed management algorithm. J Clin Hypertens (Greenwich). 2006;8(5):359-364. https://doi.org/10.1111/j.1524-6175.2005.05285.xDoumas M., Douma S. The effect of antihypertensive drugs on erectile function: a proposed management algorithm. J Clin Hypertens (Greenwich). 2006;8(5):359-364. https://doi.org/10.1111/j.1524-6175.2005.05285.xАлексеева Т.А., Литвин А.Ю., Елфимова Е.М. и соавт. Консенсус экспертов Российского медицинского общества по артериальной гипертонии. Артериальная гипертония и эректильная дисфункция. Системные гипертензии. 2021;18(2):69-79. https://doi.org/10.26442/2075082X.2021.2.200836Алексеева Т.А., Литвин А.Ю., Елфимова Е.М. и соавт. Консенсус экспертов Российского медицинского общества по артериальной гипертонии. Артериальная гипертония и эректильная дисфункция. Системные гипертензии. 2021;18(2):69-79. https://doi.org/10.26442/2075082X.2021.2.200836Julie De Backer, Kristina H Haugaa, Nina Eide Hasselberg et al. ESC Scientific Document Group, 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy: Developed by the task force on the management of cardiovascular disease and pregnancy of the European Society of Cardiology (ESC) Endorsed by the European Society of Gynecology (ESG). Eur Heart J . 2025 Aug 29:ehaf193. https://doi.org/10.1093/eurheartj/ehaf193Julie De Backer, Kristina H Haugaa, Nina Eide Hasselberg et al. ESC Scientific Document Group, 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy: Developed by the task force on the management of cardiovascular disease and pregnancy of the European Society of Cardiology (ESC) Endorsed by the European Society of Gynecology (ESG). Eur Heart J . 2025 Aug 29:ehaf193. https://doi.org/10.1093/eurheartj/ehaf193Halpern D.G., Weinberg C.R., Pinnelas R., Mehta-Lee S., Economy K.E., Valente A.M. Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(4):457-476. https://doi.org/10.1016/j.jacc.2018.10.075Halpern D.G., Weinberg C.R., Pinnelas R., Mehta-Lee S., Economy K.E., Valente A.M. Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(4):457-476. https://doi.org/10.1016/j.jacc.2018.10.075Bellos I., Pergialiotis V., Papapanagiotou A., Loutradis D., Daskalakis G. Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. Am J Obstet Gynecol. 2020;223(4):525-537. https://doi.org/10.1016/j.ajog.2020.03.016Bellos I., Pergialiotis V., Papapanagiotou A., Loutradis D., Daskalakis G. Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. Am J Obstet Gynecol. 2020;223(4):525-537. https://doi.org/10.1016/j.ajog.2020.03.016Lydakis C., Lip G.Y., Beevers M., Beevers D.G. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12(6):541-547. https://doi.org/10.1016/s0895-7061(99)00031-xLydakis C., Lip G.Y., Beevers M., Beevers D.G. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12(6):541-547. https://doi.org/10.1016/s0895-7061(99)00031-xTita A.T., Szychowski J.M., Boggess K., et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 2022;386(19):1781-1792. https://doi.org/10.1056/NEJMoa2201295Tita A.T., Szychowski J.M., Boggess K., et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 2022;386(19):1781-1792. https://doi.org/10.1056/NEJMoa2201295Malhamé I., Nerenberg K., McLaughlin K., Grandi S.M., Daskalopoulou S.S., Metcalfe A. Hypertensive Disorders and Cardiovascular Severe Maternal Morbidity in the US, 2015-2019. JAMA Netw Open. 2024;7(10):e2436478. Published 2024 Oct 1. https://doi.org/10.1001/jamanetworkopen.2024.36478Malhamé I., Nerenberg K., McLaughlin K., Grandi S.M., Daskalopoulou S.S., Metcalfe A. Hypertensive Disorders and Cardiovascular Severe Maternal Morbidity in the US, 2015-2019. JAMA Netw Open. 2024;7(10):e2436478. Published 2024 Oct 1. https://doi.org/10.1001/jamanetworkopen.2024.36478Villar J., Carroli G., Wojdyla D., et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol. 2006;194(4):921-931. https://doi.org/10.1016/j.ajog.2005.10.813Villar J., Carroli G., Wojdyla D., et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol. 2006;194(4):921-931. https://doi.org/10.1016/j.ajog.2005.10.813Brown M.C., Best K.E., Pearce M.S., Waugh J., Robson S.C., Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol. 2013;28(1):1-19. https://doi.org/10.1007/s10654-013-9762-6Brown M.C., Best K.E., Pearce M.S., Waugh J., Robson S.C., Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol. 2013;28(1):1-19. https://doi.org/10.1007/s10654-013-9762-6Cífková R., Johnson M.R., Kahan T., et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):384-393. https://doi.org/10.1093/ehjcvp/pvz082Cífková R., Johnson M.R., Kahan T., et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):384-393. https://doi.org/10.1093/ehjcvp/pvz082Drugs and Lactation Database (LactMed). https:/www.ncbi.nlm.nih.gov/books/NBK501922/ (29 January 2025, date last accessed).Drugs and Lactation Database (LactMed). https:/www.ncbi.nlm.nih.gov/books/NBK501922/ (29 January 2025, date last accessed).Ryu R.J., Eyal S., Easterling T.R., et al. Pharmacokinetics of metoprolol during pregnancy and lactation. J Clin Pharmacol. 2016;56(5):581-589. https://doi.org/10.1002/jcph.631Ryu R.J., Eyal S., Easterling T.R., et al. Pharmacokinetics of metoprolol during pregnancy and lactation. J Clin Pharmacol. 2016;56(5):581-589. https://doi.org/10.1002/jcph.631

The authors declare that there are no conflicts of interest present.